Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome

European Urology

Volumn 60, Issue 6, 2011, Pages 1235-1243

  Kälin, Martin ^a,b   Cima, Igor ^b   Schiess, Ralph ^b   Fankhauser, Niklaus ^b   Powles, Tom ^c   Wild, Peter ^b,d   Templeton, Arnoud ^a   Cerny, Thomas ^a   Aebersold, Ruedi ^b,e   Krek, Wilhelm ^b   Gillessen, Silke ^a  

^a Kantonsspital St Gallen ^*  (Switzerland)

^b ETH ZURICH   (Switzerland)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Biomarkers; Metastatic; Prognostic factors; Prostate cancer; Proteomics; PTEN

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; EPHRIN A5; MEMBRANE METALLOENDOPEPTIDASE; NECTIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEOME; THROMBOSPONDIN 1;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENETICS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MOUSE; NOMOGRAM; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SERUM;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; C-REACTIVE PROTEIN; CELL ADHESION MOLECULES; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPHRIN-A5; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MASS SPECTROMETRY; MICE; MICE, KNOCKOUT; MIDDLE AGED; NEPRILYSIN; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; PROTEOMICS; PTEN PHOSPHOHYDROLASE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; SWITZERLAND; THROMBOSPONDIN 1; TIME FACTORS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 80255124868     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.06.038     Document Type: Article

References (30)

1. S. Halabi, E.J. Small, and P.W. Kantoff Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21 2003 1232 1237 (Pubitemid 46606398)
2. O. Smaletz, H.I. Scher, and E.J. Small Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration J Clin Oncol 20 2002 3972 3982
3. A.J. Armstrong, E.S. Garrett-Mayer, and Y.C. Yang A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis Clin Cancer Res 13 2007 6396 6403 (Pubitemid 350075029)
4. F.J. Bianco Jr. Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era Urol Oncol 26 2008 408 414 (Pubitemid 351885376)
5. T.M. Beer, A.S. Lalani, and S. Lee C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial Cancer 112 2008 2377 2383
6. J. Nakashima, E. Kikuchi, and A. Miyajima Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases Urol Int 80 2008 129 133 (Pubitemid 351440504)
7. Prins RC, Brooks, L, Rademacher BA, et al. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol. In press. doi:10.1016/j.urolonc.2009. 11.012.
8. D.J. George, S. Halabi, and T.F. Shepard The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480 Clin Cancer Res 11 2005 1815 1820 (Pubitemid 40471844)
9. J.S. De Bono, H.I. Scher, and R.B. Montgomery Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 2008 6302 6309
10. T. Okegawa, K. Nutahara, and E. Higashihara Association of circulating tumor cells with tumor-related DNA in patients with hormone refractory prostate cancer Int J Urol 17 2010 466 475
11. S. Rajpar, C. Massard, and A. Laplanche Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer Ann Oncol 21 2010 1864 1869
12. M. Cully, H. You, A.J. Levine, and T.W. Mak Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis Nat Rev Cancer 6 2006 184 192 (Pubitemid 43292562)
13. A.H.M. Reid, G. Attard, and L. Ambrosine Molecular characterization of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer Br J Cancer 102 2010 678 684
14. K. Sircar, M. Yoshimoto, and F.A. Monzon PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer J Pathol 218 2009 505 513
15. I. Cima, R. Schiess, and P. Wild Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer PNAS 108 2011 3342 3347
16. B. Domon, and R. Aebersold Options and considerations when selecting a quantitative proteomics strategy Nat Biotechnol 28 2010 720 721
17. Therneau T, Lumley T. Survival: survival analysis, including penalised likelihood. R package v.2.35-4. 2009. http://CRAN.R-project.org/package= survival.
18. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2009.
19. D.G. Altman, B. Lausen, W. Sauerbrei, and M. Schumacher Dangers of using "optimal" cutpoints in the evaluation of prognostic factors JNCI 86 1994 829 835 (Pubitemid 2100935)
20. Ishwaran H, Kogalur UB. randomSurvivalForest: random survival forests. R package v.3.6.0. 2009. http://CRAN.R-project.org/package=randomSurvivalForest.
21. Heagerty PJ, Saha P. SurvivalROC: time-dependent ROC curve estimation from censored survival data. R package v.1.0.0. 2009.
22. L. Breiman Random forests Machine Learning 45 2001 5 32 (Pubitemid 32933532)
23. A.J. Armstrong, I.F. Tannock, R. de Witt, D.J. George, M. Eisenberger, and S. Halabi The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival Eur J Cancer 46 2010 517 525
24. A.Y. Liu, M.P. Roudier, and L.D. True Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile Am J Pathol 165 2004 1543 1556 (Pubitemid 39435154)
25. C.N. Papandreou, B. Usmani, and Y. Geng Neural endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression Nat Med 4 1998 50 57 (Pubitemid 28133079)
26. M.W. Shafer, L. Mangold, A.W. Partin, and B.B. Haab Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease Prostate 67 2007 255 267
27. T. Kalinski, A. Ropke, and S. Sel Down-regulation of ephrin-A5, a gene product of normal cartilage, in chondrosarcoma Hum Pathol 40 2009 1679 1685
28. T.L. Romanuik, T. Ueda, and N. Le Novel biomarkers for prostate cancer including noncoding transcripts Am J Pathol 175 2009 2264 2276
29. Y. Takai, J. Miyoshi, W. Ikeda, and H. Ogita Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation Nat Rev Mol Cell Biol 9 2008 603 615 (Pubitemid 352032927)
30. G. Guzman, S. Oh, D. Shukla, and T. Valyi-Nagy Nectin-1 expression in the normal and neoplastic human uterine cervix Arch Pathol Lab Med 130 2006 1193 1195 (Pubitemid 44168790)